Drug Detail

Information about BKM120

Generic Name
IND
BKM120
Brand Name (US)
Manufacturer
Novartis
Drug Type
Kinase inhibitor
Delivery
Oral
Approval Status
Phase 1
Indications
Overall Strategy
Oncogenic Signal Path Based
Strategy
Block KIT Signal Path
Drug Category
PI3K inhibitor

BKM120 is a selective PI3K inhibitor made by Novartis. It is in phase I trials at the Sarah Cannon Research Institute.
Unlike BEZ235 and BGT226 (also from Novartis), BKM120 does not inhibit the mTOR pathway.
A phase I trial combining BKM120 and 400 mg of imatinib is listed as not yet recruiting in clinicaltrials.gov (Nov. 22nd, 2011).